Comparison of Granisetron and Dexmedetomidine and Lidocaine in reduce Etomidate injection pain

Comparison of Granisetron and Dexmedetomidine and Lidocaine in reduce ?Etomidate injection pain in elective surgery

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016122720258N21

Enrollment

132

Registered

2017-04-10

Start date

2016-10-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

General surgery. Procedure for purposes other than remedying health state, unspecified

Interventions

Intervention 1: Intervention group: We inject 6 milligram Granisetron : we inject 2 milliliter Granisetron in one vein of ?hand and 2 milliliter Normal saline 0/9 % in other vain of hand simultaneou

Treatment - Drugs

Intervention group: We inject 6 milligram Granisetron : we inject 2 milliliter Granisetron in one vein of ?hand and 2 milliliter Normal saline 0/9 % in other vain of hand simultaneously.?

Intervention group: We inject 2 milligram Lidocain: we inject 40 milligram Lidocain in one vein of hand ?and 2 milliliter Normal saline 0/9 % in other vein of hand simultaneously.

Intervention group: We inject 5 microgram: we inject 20 milliliter Dexmedetomidine in one vein of hand ?and 2 milliliter Normal saline 0/9 % in other vein of hand simultaneously.?

In control group: We inject 2 ?milliliter Normal saline 0/9 % in other ?hand simultaneously for intervention hand in ?control group

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 18 to 50 years; ASA I and II Exclusion criteria: lack of control blood pressure; history of vascular disease; addiction to opioids; incidence of thrombolytic; diabetes ; chronic pain; history of tumor; burns in two hands; contra-indicated for injection Granisetron and Dexmedetomidine and Lidocaine

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: After injection drug and 5 minute after injection. Method of measurement: Visual Analogue Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Esmaeel Moshiri

Arak University of Medical Sciences

modir.he@gmail.com+98 86 3222 2003

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026